About Synapsin-2
Synapsin-2 (SYN2) is a protein
from Homo sapiens identified by UniProt accession
Q92777, 582 residues long.
MolForge cross-references it against 0 known binders and
181 disease associations.
Target properties
| Protein name | Synapsin-2 |
| UniProt accession | Q92777 |
| Gene | SYN2 |
| Organism | Homo sapiens |
| Length | 582 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (181)
Diseases linked to this target (Open Targets).
- blood protein measurement · score 0.42
- schizophrenia · score 0.41
- creatinine measurement · score 0.37
- glomerular filtration rate · score 0.32
- triglyceride measurement · score 0.28
- platelet count · score 0.28
- drug use measurement · score 0.28
- psychiatric disorder · score 0.27
- nervous system disease · score 0.27
- eye disease · score 0.27
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q92777-F1 | alphafold | PREDICTED | 73.90 | — |
Amino-acid sequence (582 residues)
MMNFLRRRLS DSSFIANLPN GYMTDLQRPE PQQPPPPPPP GPGAASASAA PPTASPGPER RPPPASAPAP QPAPTPSVGS SFFSSLSQAV KQTAASAGLV DAPAPAPAAA RKAKVLLVVD EPHADWAKCF RGKKVLGDYD IKVEQAEFSE LNLVAHADGT YAVDMQVLRN GTKVVRSFRP DFVLIRQHAF GMAENEDFRH LIIGMQYAGL PSINSLESIY NFCDKPWVFA QLVAIYKTLG GEKFPLIEQT YYPNHKEMLT LPTFPVVVKI GHAHSGMGKV KVENHYDFQD IASVVALTQT YATAEPFIDS KYDIRVQKIG NNYKAYMRTS ISGNWKTNTG SAMLEQIAMS DRYKLWVDTC SEMFGGLDIC AVKAVHGKDG KDYIFEVMDC SMPLIGEHQV EDRQLITELV ISKMNQLLSR TPALSPQRPL TTQQPQSGTL KDPDSSKTPP QRPPPQGGPG QPQGMQPPGK VLPPRRLPPG PSLPPSSSSS SSSSSSAPQR PGGPTTHGDA PSSSSSLAEA QPPLAAPPQK PQPHPQLNKS QSLTNAFSFS ESSFFRSSAN EDEAKAETIR SLRKSFASLF SD
Explore Synapsin-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets